Thank you for registering your account
Thanks for joining touchIMMUNOLOGY to hear about news and updates from across the Immunology community.
We’ve sent you an email to verify your email address. Please click on the link to confirm your account.
You can review your email preferences at any time or update your account details
Strategies for the management of chronic rhinosinusitis with nasal polyps: Expert insight in optimizing care
Watch a panel of experts discuss challenges in the diagnosis of CRSwNP and considerations for optimal management of the disease.
- Define diagnostic criteria for CRSwNP
- Recognize that eosinophilic inflammation in CRSwNP is a predictor of disease recurrence
- Outline advancements in the treatment of CRSwNP
Eosinophilic inflammatory diseases of the respiratory system: New therapeutic options
Watch a panel of experts discuss how to identify and manage patients with inflammatory respiratory diseases, with a focus on severe eosinophilic asthma.
- Recognize the role of eosinophils and type 2 inflammation in respiratory disease
- Understand the diagnostic methods used to differentiate inflammatory diseases of the respiratory system
- Recall disease states that may benefit from therapies that target the complex interaction between eosinophils and their environment
Victoria P. Werth, ACR 2022: The phase 3 DeterMine trial of lenabasum in dermatomyositis
DeterMine (NCT03813160) was a phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of lenabasum for the treatment of dermatomyositis. It was a pleasure to talk with Prof. Victoria P. Werth (University of Pennsylvania, Philadelphia, PA, USA) to discuss the aims, design, eligibility criteria and findings of the phase 3 study. This information […]
Nancy Lane, ACR 2022: Romosozumab for knee osteoarthritis in postmenopausal women – findings from a substudy of the FRAME clinical trial
The FRAME clinical trial (NCT01575834) was a phase 3 randomised, double-blind, placebo-controlled study, that investigated the efficacy and safety of romosozumab in postmenopausal women with osteoporosis (OP); the knee osteoarthritis (OA) substudy assessed the effect of treatment with romosozumab on the progression of OA of the knee in women with OP and knee OA. In […]
Paul Emery, ACR 2022: Peresolimab for the treatment of rheumatoid arthritis – findings from a phase 2 trial
Peresolimab, a humanised immunoglobulin G1 monoclonal antibody, was investigated in a phase 2a, randomized, double-blind, placebo-controlled clinical trial for the treatment of moderately to severely active rheumatoid arthritis (RA) (NCT04634253). In this touchIMMUNOLOGY interview, we were delighted to speak with Dr. Paul Emery (University of Leeds, Leeds, UK) around the rationale for targeting the programmed […]
Sofia Ramiro, ACR 2022: Ixekizumab for radiographic axial spondyloarthritis – findings from the COAST-V trial
The COAST-V trial (NCT02696785) investigated the efficacy and safety of ixekizumab in patients with radiographic axial spondyloarthritis who were biological disease-modifying anti-rheumatic drug naïve. It was a pleasure to talk with Dr. Sofia Ramiro (Leiden University Medical Center, Leiden, Netherlands) to discuss the findings in terms of patient reported outcomes at weeks 16 and 52 […]
The Complement System in Spondyloarthritis: What Do We Know?
touchREVIEWS in RMD. 2022;2(1):50–6 DOI: https://doi.org/10.17925/RMD.2022.1.2.50
The term spondyloarthritis (SpA) encompasses a number of disease entities that share common clinical, biological and genetic characteristics. Common clinical features include inflammation in the axial skeleton, including the spine and sacroiliac joints, and inflammation of peripheral musculoskeletal structures such as arthritis, enthesitis and dactylitis.1 The disease is therefore divided by (predominantly) axial or peripheral manifestations. […]
Is There a Place for Complement Inhibition with Monoclonal Anti-C5a Antibody Vilobelimab in the Treatment of Patients with ANCA-associated Vasculitis?
touchREVIEWS in RMD. 2022;1(2):46–9 DOI: https://doi.org/10.17925/RMD.2022.1.2.46
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a spectrum of disorders primarily affecting the small blood vessels in various organs. It often affects the kidneys, causing rapidly progressive renal failure due to necrotizing crescentic glomerulonephritis. Another major cause of mortality in AAV is life-threatening pulmonary haemorrhage. Historically, AAV has been divided into granulomatosis with polyangiitis […]
Can I Prevent Developing a Rheumatic and Musculoskeletal Disease Through Lifestyle Changes? A Focus on Nutrition
touchREVIEWS in RMD. 2022;1(2):44–5 DOI: https://doi.org/10.17925/RMD.2022.1.2.44
Reducing the risk of rheumatic and musculoskeletal disease (RMD) is crucial to prevent associated chronic disease burden. However, the process is complex because the aetiopathological factors contributing to disease onset are not entirely understood. Healthy eating based on the Mediterranean diet (MD) can effectively prevent many chronic conditions and, potentially, RMD. Together with physical activity, […]
Avacopan: An Oral Complement 5a Inhibitor for ANCA-associated Vasculitis
touchREVIEWS in RMD 2022;1(1):23–8 DOI: https://doi.org/10.17925/RMD.2022.1.1.23
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) includes several distinct clinical entities: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA) and renal-limited vasculitis. What all these diseases have in common is the presence of serum autoantibodies, designated as ANCA, that react with antigens in the cytoplasm of neutrophilic granulocytes and monocytes.1,2 The […]